Dr. Dietrich on Optimizing Treatment Options for Patients in MCL

In Partnership With:

Partner | Oncology Network Providers | <b>Florida Cancer Specialists & Research Institute</b>

Martin Dietrich, MD, PhD, discusses optimizing treatment options for patients with mantle cell lymphoma.

Martin Dietrich, MD, PhD, physician, Florida Cancer Specialists & Research Institute, assistant professor of internal medicine, University of Central Florida, discusses optimizing treatment options for patients with mantle cell lymphoma (MCL).

MCL has evolved into a complex disease, requiring both community and academic oncologists to present a patient with all their treatment options, Dietrich says. Moreover, the involvement of an academic center is vital for transplant and CAR T-cell therapy to optimize treatment, Dietrich adds. Although CAR T-cell therapy is not yet broadly available, it is an option worth discussing, Dietrich continues.

The opportunity to enroll in clinical trials and utilize innovative cell-based therapies that should be reviewed in a multidisciplinary setting, Dietrich explains. Patients with MCL continue to face a high-risk disease, and using a multidisciplinary approach is key for optimizing outcomes and simplifying the experience for patients, Dietrich concludes.